Grand Life Sciences Group

In the blood products segment, Grand Life Sciences relies on its high-tech subsidiary Grand Shuyang Life Sciences (Chengdu) Co., Ltd. (“Grand Shuyang”) to establish a dual-engine development model. With Chengdu as the plasma-derived blood product development platform and Beijing as the recombinant blood product development platform, the company has achieved full coverage across plasma-derived products, recombinant proteins, and gene therapy technologies in the blood products field. This integrated approach has enabled the establishment of one of the most comprehensive blood product pipelines globally, positioning Grand Shuyang as a leading blood products enterprise with full lifecycle drug coverage, advanced capabilities in the expression of complex recombinant proteins, domestic leadership, and global competitiveness. The product portfolio spans three major categories—albumin, immunoglobulins, and coagulation factors, making Grand Shuyang one of the enterprises in China’s blood products industry with high plasma utilization efficiency, a complete product range, and diverse specifications. Grand Shuyang has built an internationally leading Industry 4.0 intelligent manufacturing base for blood products, enabling full-chain coverage of market demand and establishing itself as a globally leading industrialization base for blood products. The company holds exclusive commercialization rights in China for the globally innovative anti-TFPI monoclonal antibody KN057, developed for the treatment of hemophilia. KN057 has initiated two Phase III clinical trials in China and, in 2024, was granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA).

In the probiotics field, the company has established a proprietary strain bank comprising tens of thousands of functional strains and is developing a new generation of microbiome-based live biotherapeutic products. Grand Life Sciences’ core entity in Hangzhou focuses on gastrointestinal management, metabolic health, and microbiome wellness. Its new 96-mu facility houses the world’s leading large-scale fermentation base for live bacteria and a nationally accredited laboratory for live biotherapeutic products. It is also one of the most automated, continuous-production, and commercially diverse live biotherapeutic manufacturing sites in the world. The company’s core product—Bifidobacterium Quadruple Live Tablets—has maintained leading market share for many years and is listed as a top-tier recommendation in clinical treatment guidelines. In the metabolic field, the company’s Class-1 innovative drug PEG-uricase injection for treating hyperuricemia with gout is currently in Phase II clinical trials. The company is committed to becoming a global leader in lifestyle-oriented gut–axis solutions. Leveraging strong scientific research capabilities and a solid industrial foundation, it is building an efficient strain discovery and screening system, and developing science-based probiotic health products in response to market needs. In 2025, the company will launch the world’s first dual-chamber fresh live probiotic product—GUTX—ushering probiotic science-based health products from the powder-based 3.0 era into a new 4.0 era of dual-chamber fresh live formulations.

In the vaccine field, Grand Life Sciences has established a vertically integrated and internationalized industrial layout covering R&D, manufacturing, and commercialization. It is one of China’s leading innovative vaccine enterprises, distinguished by advanced technologies and a robust product pipeline. With four proprietary technology platforms—recombinant protein VLPs, novel adjuvants, bacterial gene editing, and small nucleic acids—the company has built a solid foundation for innovation. It now maintains over ten Class-1 innovative vaccine candidates, including several global first-in-class projects. In hepatitis B prevention, the company is developing China’s first novel-adjuvant HBV prophylactic vaccine, designed to provide population-wide protection with fewer doses and faster immune response. Its globally first-in-class functional-cure therapeutic HBV vaccine offers new hope for clinical cure, representing a critical breakthrough toward achieving the “final step” in HBV eradication. The company is also advancing a strategic pipeline of small-nucleic-acid therapeutics to address the challenge of patients with persistently high HBsAg levels, thereby establishing an integrated Chinese solution for HBV—from prevention to cure. It also owns the world’s first recombinant tetanus vaccine, a hexavalent recombinant norovirus vaccine, and several domestically leading combination vaccines—together forming a multi-tiered, structured matrix of innovative products. In addition, a vaccine industrialization base built to global high standards has commenced construction in Hangzhou. Upon completion, the facility will support the commercial production of 8–10 novel vaccines, with an expected annual output value exceeding RMB10 billion.

Grand Life Sciences has cultivated its presence in the perioperative field for many years, particularly in the segments of hemostasis and analgesia. Its core product, Hemocoagulase Bothrops Atrox (brand name: Baquting®), has maintained a leading market share for many consecutive years. The new product—Recombinant Human Thrombin, a Class 3 therapeutic biologic (brand name: Zepuning®)—is the only recombinant human thrombin in China produced via gene-recombination technology. It was approved for marketing in 2024, with the company holding exclusive commercialization rights in China. Leveraging its product cluster advantages, Grand Life Sciences continues to strengthen its leadership in the domestic hemostasis market. The company also possesses several key pipeline products—including the Class 1 innovative biologic Collagenase for Injection and the exclusively marketed Collagenase Ointment. While rapidly expanding market coverage, it is simultaneously conducting multiple post-marketing studies targeting new indications and new patient populations, continuously unlocking the potential of its core product portfolio.

In the field of medical nutrition, Grand Life Sciences leverages its complex formulation platform to address health needs arising from population aging, the chronic progression of tumors, and increasingly precise treatment paradigms. The company is building a pipeline that takes amino acids as the foundation, integrates both parenteral and enteral nutrition, and supports full-cycle nutrition management. More than ten new products have been deployed across pediatric nutrition, elderly nutrition, and oncology nutrition.